Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg

– Company secures next step to continue to build-out pipeline of assets- University researchers developed a proprietary and orally active bacterial vaccine platform technology currently undergoing pre-clinical studies for the prevention of coronavirus diseases,...

Aeterna Zentaris to Present at NobleCon17

– Live video webcast with CEO, Dr. Klaus Paulini, onWednesday, January 20th at 12:00 PM ET -CHARLESTON, S.C., Jan. 15, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical...